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Abstract Chronic obstructive pulmonary disease (COPD) is a disease state characterized by chronic airtlow limitation 
that is not fully reversible, with a precise definition varying between different management guidelines. 
The burden of COPD is considerable from all relevant viewpoints. From the perspective of society, the mortality is already 
considerable, and it is likely to increase from the sixth to the third most common cause of death worldwide by 2020. From 
the patient’s perspective, COPD is responsible for disability that restricts many everyday activities, such as walking up stairs. 
The burden of COPD on physicians includes increasing consultations for the condition. From the perspective of healthcare 
payers, COPD represents an increasing burden, primarily due to the costs incurred when exacerbations require hospital 
treatment. 
Despite this considerable burden, there are many signs that the impact of COPD is not recognized. Research on COPD 
is currently underfunded in relation to the impact of the disease; patients only present late with symptoms; physicians may 
fail to diagnose the condition and healthcare payers may be failing to support treatment approaches that could reduce 
the number of costly hospital exacerbations. Reasons for this overall poor recognition of the burden of COPD include 
lack of recognition of the disease, difficulties in diagnosis, poor knowledge of COPD and nihilistic attitudes towards the 
condition and its treatment. 
Awareness of COPD could be improved with education of the public and healthcare professionals. Long-term 
epidemiological studies showing the impact on morbidity and mortality of different treatment approaches would also 
influence the setting of priorities by healthcare payers. 
0 2002 Elsewer Science Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a 
disease state characterized by airflow limitation that is 
not fully reversible.The airtlow limitation is usually both 
progressive and associated with an abnormal inflam- 
matory response of the lungs to inhalation of noxious 
particles or gases (I). However, COPD is not a disease 
that can be readily diagnosed since airflow limitation must 
be measured using spirometry. Diagnosis of COPD is 
further complicated by the discrepancy frequently 
observed between symptoms and the degree of airflow 
limitation, and by the need to differentiate from asthma. 
The lung function definition of airflow limitation in COPD 
varies according to different guidelines (Table I). These 
factors complicate the study of COPD epidemiology, as 
well as the assessment of the burden of the disease. 
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This paper examines the burden of COPD from the 
perspective of society, the patient, the physician managing 
the disease, and the healthcare payer.Although the burden 
is considerable from all these perspectives, attitudes 
towards the disease seem to prevent appropriate actions 
being taken to address the problems caused.The attitudes 
contributing to lack of appreciation of the impact of 
COPD are also considered, together with future actions 
that could be taken to address these issues. 
BURDEN OF COPD FROM THE 
PERSPECTIVE OF SOCIETY 
World prevalence of COPD is estimated at 9.34/1000 
among males (all ages) and 7*33/ IO00 females (all ages) (2). 
The prevalence of COPD varies in different countries, 
reflecting previous smoking habits among other factors. 
Estimates for males (all ages) range from 26*20/1000 in 
China to 2.691 IO00 in the Middle Eastern crescent. Even 
within individual countries, wide variation is seen in 
COPD prevalence. In Spain, for example, the IBERPOC 
study of COPD prevalence in subjects aged 40-69 years 
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FIGURE I. Prevalence of COPD In seven regions of Spain (3). 
of different provinces found a more than three-fold 
variation (Fig. I) (3). Not surprisingly, the recorded 
prevalence of COPD greatly varies with the age group 
under study, and also varies with the definition used (4). 
Mortality from COPD is considerable. In 2000, the 
World Health Organisation estimated that there were 
2.74 million deaths from COPD, worldwide (5). Further- 
more, the mortality rate from COPD is increasing. 
Although in 1990 COPD was ranked sixth in the list of 
mortality causes worldwide, it is expected to reach third 
place by 2020 (6). In the U.S.A., the age-adjusted death 
rate for COPD rose between 1965 and 1998, while it 
fell for coronary heart disease, stroke and other cardio- 
vascular diseases (Fig. 2) (l,7). In the U.S.A., COPD is 
now the fourth leading cause of death (behind heart 
disease, cancer and cerebrovascular disease). Even 
though COPD is mainly a disease affecting elderly 
people, there is still a high potential for loss of life-years. 
Analysis of data from the Flemish regional registration 
agency in Belgium showed that COPD accounted for 
more life-years lost among males aged l-74 years than 
heart failure (8,9). 
Society has to bear the economic impact of COPD, 
which covers the direct medical costs (considered in 
more detail below) and the indirect costs arising from 
the need for disability and pension payments, the 
consequences of sick leave from employment and the 
losses arising from early mortality. 
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FIGURE 2. Rate of changes in adjusted death rates in the U.S.A. between I965 and I998 for four major causes of disease and for all 
other causes grouped (I ,j) 
BURDEN OF COPD FROM THE 
PERSPECTIVE OF THE PATIENT 
In any assessment of the burden of a disease, the impact 
on the patient is of primary importance, though it is 
often forgotten. Understanding this perspective requires 
careful questioning of patients themselves. A recent 
large-scale study (Confronting COPD) has tried to 
assess the burden of COPD on patients in the U.S.A., 
Canada, U.K., France, Germany, Netherlands, Italy and 
Spain (IO). In this study, over 200 000 households across 
the eight countries were telephoned at random and 
approximately 400 people were identified in each 
country who were aged 45 years or older, had smoked 
during the last IO years and had received a diagnosis of 
COPD, emphysema or chronic bronchitis. These 
respondents were then asked detailed questions about 
symptoms and their impact on quality of life. Although 
lung function testing could not be included to confirm 
the diagnosis, the results, nevertheless, reveal an 
interesting picture.The majority of respondents reported 
frequent troublesome symptoms, with 22-70% of 
respondents reporting shortness of breath experienced 
every day or on most days for a 3-month period during 
the year preceding the research, and 45-67% reporting 
coughing every day or most days for a similar period 
(Fig. 3). Respondents also reported severe limitation of 
effort, with the majority (ranging from 53% in the 
Netherlands to 73% in the U.S.A.) reporting that they 
felt breathless when simply walking up stairs. The 
symptoms of COPD impaired other everyday activities 
for many respondents (Fig. 4). In other studies using well- 
validated quality of life questionnaires, such as the St 
George’s Respiratory Questionnaire, COPD has been 
shown to have a marked adverse impact (I I, 12). 
BURDEN OF COPD FROM THE 
PERSPECTIVE OF THE PHYSICIAN 
Between 1985 and 1995, the number of physician office 
visits for COPD in the U.S.A. increased from 9.3 million 
to I6 million.The view of an increasing burden of COPD 
on physicians was confirmed in the Confronting COPD 
study, which surveyed 625 primary care physicians and 
280 respiratory specialists across eight countries (IO). Of 
the 3265 patients from eight countries responding to this 
study, 70% reported that consultations for the disease 
were most frequently with primary care physicians. Most 
of the physician respondents (ranging from 52% in the 
U.K. to 85% in the Netherlands, France and Italy) 
considered that the prevalence of COPD had increased 
during the last IO years. In addition to the burden on 
primary care physicians, COPD also has considerable 
impact on hospital physicians. For example, the number 
of hospitalizations for COPD in the U.S.A. was estimated 
at nearly 500 000 in I995 ( 13). Reflecting the increase in 
prevalence, hospital admissions for COPD are rising, in 
the U.K. (14) and other countries. The increase in 
hospital-days is predicted to increase further over the 
next 20 years or so (I 5). 
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FIGURE 3. Proportion of patients (~3265) of eight countries reporting symptoms of coughrng and shortness oi breath present 0~ 
every or most days during the worst 3 months of the year preceding the survey (/ 0). 
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FIGURE 4. Activities reported to be lImited by symptoms of COPD (I 0) In 3265 subject> of eight countries 
BURDEN OF COPD FROM THE the U.S.A., for example, the direct medical costs of 
PERSPECTIVE OF THE HEALTHCARE managing COPD (including hospital stays, outpatient 
PAYER visits and treatments) amounted to $14.7 billion in I993 
(I). Such costs are increasing, as seen for example in 
Hospital care is costly, so the burden of hospitalized Sweden (Fig. 5) (I 6,I7). Although increasing hospitali- 
COPD patients on healthcare payers is considerable. In zation costs are the main cause of increased expenditure 
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FIGURE 5. Increases in direct costs for COPD management in Sweden between I980 and I99 I (I 6) 
on COPD, other factors are also likely to contribute in 
the future (Table 2). Furthermore, current initiatives to 
reduce smoking behaviour will not materially affect the 
projected increase in costs in the medium-term, due to 
the long-term nature of the disease (I 8). 
ISTHE BURDEN OF COPD 
RECOGNIZED? 
Clearly, from the perspectives of society, patients, 
physicians and healthcare payers, COPD represents a 
considerable burden that will increase with the ageing 
population and as the toll from previous use of tobacco 
becomes manifest. However, there are worrying signs 
that this burden is not recognized. 
prominently among the priorities of governments. 
However, this does not appear to be the case. In the 
U.K., there are National Service Frameworks highlighting 
the conditions that are recognized as important 
priorities for the National Health Service, but although 
these include heart disease, care of the elderly and 
smoking cessation, COPD is not specifically targeted. In 
the U.S.A., National Institutes of Health research funding 
for COPD is considerably below that which could be 
predicted from the burden imposed by the disease, in 
terms of impact on disability-adjusted life years, mortality 
and years of life lost, while research on acquired 
immunodeficiency syndrome (AIDS) receives funding out 
of all proportion to the impact of the disease on these 
three parameters (Fig. 6) ( 19). 
Society Patients 
If society recognized the extent of the burden currently If patients recognized the impact that COPD could have 
imposed by COPD, and predicted for the future, it would on them, smoking behaviour would be curtailed and 
be reasonable to expect the condition to feature symptoms of cough, wheeze, breathlessness and sputum 
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disability-adjusted life-years ( 19). 
production would be rapidly reported. But this does not 
happen. While there is wide public recognition of the 
association between smoking and cancer or heart 
disease, there is less awareness of the link with COPD. 
Symptoms of COPD are, correctly, ascribed to the 
impact of smoking, without appreciating that a defined 
medical condition has developed. This lack of under- 
standing of COPD results in a delay in presenting to a 
physician and receiving treatment that could improve 
symptom control and delay the decline in lung function 
and quality of life. The Confronting COPD survey 
confirmed these views, with the finding that the majority 
of both patients (85% of respondents) and physicians 
(93% of respondents) thought that patients required 
more education on the disease (IO). 
Physicians 
If physicians were more aware of the burden of COPD, 
diagnosis of the disease could occur at an early stage, 
while treatment of the condition, including smoking 
cessation, would be intensive to ensure maximum 
control of symptoms and to maintain quality of life as 
long as possible.Yet, all the indications are that this does 
not happen.There may be at least as many patients with 
undiagnosed COPD as those already diagnosed: where 
population studies using spirometric assessment have 
been carried out on smokers, a high proportion has been 
found to have COPD or impaired lung function that 
could progress to COPD (20). Patients who smoke and 
present with regular acute exacerbations of COPD may 
be treated as if they suffer from repeated respiratory 
infections, without examination of the underlying 
disease. When the diagnosis is made, the condition may 
already be well-advanced with a serious decline in lung 
function. The general physician’s ability to access and 
interpret spirometric assessment is limited, impairing the 
early diagnosis of COPD. Even when diagnosis has been 
made, prescribing of anything other than flu vaccination 
is limited (IO). 
Healthcare payers 
If those paying for healthcare for patients with COPD 
recognized the current and future burden of the disease, 
they would be taking steps now to encourage smoking 
cessation and earlier diagnosis. Spirometric screening of 
all heavy smokers could be used to detect those at an 
early stage in disease development to target for smoking 
cessation advice - this could well be more cost-effective 
than widely accepted screening programmes for cervical 
and breast cancer. If healthcare payers appreciated the 
burden of admissions from acute COPD exacerbations, 
there would be greater support for community-based 
management programmes and drug treatments that 
reduce exacerbations. Yet healthcare payers do not 
appear to be taking such actions, providing mostly little 
financial support for smoking cessation programmes. 
BURDEN OF COPD 
FACTORS LEADING TO POOR 
RECOGNITION OFTHE BURDEN OF 
COP0 
A number of inter-linked factors can be identified that 
contribute to the poor recognition of the burden of COPD. 
Poor recognition 
Patients fail to recognize the early symptoms of COPD. 
Symptoms may be attributed to smoking itself, rather 
than to the early stages of a specific medical condition. 
This means that they do not present for diagnosis, and fail 
to receive a medical label for the symptoms they 
experience. It would be interesting to investigate the 
relative success of smoking interventions in people during 
early middle age given a medical diagnosis, compared with 
those who do not receive a medical label. It could be 
postulated that the patients given early warning of their 
condition may take more active steps to stop smoking, in 
the same way that many patients who suffer an early 
heart attack make drastic changes to their lifestyle. 
Difficulties in diagnosis 
In practice, the diagnosis of COPD is essentially one of 
exclusion - airflow obstruction that is not readily 
reversible (i.e. asthma), sputum production that is not 
due to bronchiectasis, symptoms of breathlessness, and 
more rarely chest pain, that are not due to congestive 
heart failure or coronary heart disease. Symptoms of 
COPD bear relatively little relation to the degree of 
airflow limitation, so that lung function tests are required 
for diagnosis. Even the various professional organizations 
do not agree on a specific diagnosis of COPD. It is, 
therefore, hardly surprising that the diagnosis of COPD 
presents a barrier to the ready recognition of the disease 
and, consequently, its burden. 
Poor knowledge of the disease 
Among the public and healthcare professionals alike, 
knowledge of COPD is poor. Physicians may be unaware of 
recent developments regarding pathogenesis and therapy 
However, there is still far from complete understanding of 
the various pathological processes that lead to the various 
basic features of COPD (e.g. emphysema, small airway 
disease, chronic mucus hypersecretion). Without a good 
understanding of the pathophysiology of the disease, 
physicians may be reluctant to give treatments, even those 
empirically shown to bring patient benefits. 
Nihilistic attitudes towards COP0 
A major problem limiting awareness of the burden of 
COPD is the nihilistic attitude shown towards the 
s9 
condition, among patients, healthcare professionals and 
healthcare payers alike.There is an overwhelming feeling 
that the condition is brought on by the actions - mostly 
smoking - of the patient, and that nothing can be done 
about the disease, once it develops.Treatments are seen 
to have limited benefits on symptoms and quality of life, 
while long-term data showing the impact of treatments 
on ‘hard’ endpoints, such as lung function and mortality, 
are lacking. Since priority setting among healthcare 
payers inevitably involves consideration of health gain 
that can be achieved, COPD is given poor consideration. 
RAISING AWARENESS OF THE 
BURDEN OF COPD 
If COPD is to be moved up the healthcare agenda, it is 
important that the extent of the burden it imposes is 
recognized. This means that the factors impeding 
recognition of the burden must be addressed. Public 
education through prolonged media campaigns and via 
consultations with healthcare professionals is required to 
ensure earlier presentation with symptoms. Support for 
professional education is also required, to lower the 
threshold of suspicion for COPD, and to ensure that 
diagnosis takes place at the earliest opportunity, Regular 
spirometric assessments of all smokers over the age of 
45 years could be a good way of detecting patients either 
with early stage COPD or those at risk of developing the 
disease.Training of healthcare professionals to carry out 
and interpret spirometry effectively is also required. 
Research on the underlying pathophysiology of the 
disease should be widely disseminated, and used to 
stimulate further research on the condition: this could 
help in the search for new and innovative therapies. 
Other areas requiring further research include long- 
term epidemiological studies to assess the impact of 
different treatment approaches on mortality and 
morbidity: such studies would carry considerable weight 
with healthcare payers. Demonstrating that the 
progression of the disease could be affected by the 
management approach taken would also go a very long 
way to dispel nihilistic attitudes towards COPD among 
patients, physicians and healthcare payers alike. 
CONCLUSIONS 
The available evidence points to the considerable burden 
of COPD, from the perspectives of society, patients, 
physicians and healthcare payers. The disability imposed 
by the condition has a major economic consequence that 
is likely to increase in the foreseeable future. Despite 
this, the burden of COPD is not widely recognized, in 
large part due to poor recognition, diagnosis and 
knowledge of COPD, and also to nihilistic attitudes 
towards the condition. Education of both the public and 
healthcare professionals could help to increase 
SIO RESPIRATORY MEDICIINE --__ ___- 
awareness of the burden of COPD, while further 
research, particularly long-term epidemiological studies 
demonstrating the impact of different treatment 
approaches on mortality, would give healthcare payers 
the information needed to justify expenditure on the 
condition. 
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